A Multi-Centre, Double-Blind, Randomised, Placebo-Controlled Parallel-Group Study to Assess the Tolerability of ToleroMune House Dust Mite in Subjects With Controlled Asthma and House Dust Mite-Induced Rhinoconjunctivitis
Phase of Trial: Phase II
Latest Information Update: 22 Apr 2015
Price : $35 *
At a glance
- Drugs HDM SPIRE (Primary)
- Indications Allergic rhinoconjunctivitis
- Focus Adverse reactions
- Sponsors Circassia
- 10 Jun 2014 According to ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
- 14 May 2014 According to ClinicalTrials.gov record, status changed from recruiting to active, no longer recruiting.
- 28 Sep 2013 New trial record